FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113180393> ?p ?o ?g. }

• W3113180393 abstract "<h3>Background</h3> Spherical nucleic acids (SNAs) are nanostructures consisting of radially oriented, densely packed oligonucleotides arranged in a spherical 3D architecture. SNAs have different properties than linear oligonucleotides, including increased cellular uptake, which may enhance efficacy. Cavrotolimod (AST-008) is an SNA toll-like receptor 9 (TLR9) agonist designed to robustly activate innate and adaptive immune responses. Cavrotolimod is in development for the treatment of advanced solid tumors in combination with PD-1 blockade. Prior studies demonstrated that cavrotolimod, alone and in combination with PD-1 blockade, increased circulating levels of Th1-type cytokines and activated peripheral T cells and NK cells. <h3>Methods</h3> AST-008-102 is an ongoing Phase 1b/2 study (NCT03684785). The Phase 1b dose escalation stage examined intratumoral (IT) cavrotolimod at doses of 2, 4, 8, 16, and 32 mg in combination with pembrolizumab in patients with advanced solid tumors. Cavrotolimod was dosed once weekly for 8 weeks and once every 3 weeks thereafter. The Phase 2 dose expansion stage is examining cavrotolimod 32 mg IT in combination with IV pembrolizumab for the treatment of advanced Merkel cell carcinoma (MCC) and in combination with IV cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma (CSCC). Both cohorts are enrolling patients with documented progression of disease on PD-(L)1 blockade. This analysis provides interim results of the Phase 1b stage. <h3>Results</h3> In the Phase 1b stage, 20 patients were enrolled across all planned dose levels. No dose-limiting toxicities, grade (G)4 toxicities, or treatment-related serious adverse events (AEs) were observed. The most common AEs were injection site reactions (ISRs) and flu-like symptoms. All treatment-related AEs were < G3 except agitation and ISR (1 each). At data cutoff, ORR is 21% (4 of 19 evaluable patients) in a heterogeneous population with solid tumors. All 4 responders (2 melanoma and 2 MCC patients) have ongoing responses, with duration of response exceeding 52 weeks in 2 patients. Three of 4 responders had disease progression on PD-1 blockade at the time of enrollment, and one patient had a prior response to PD-1 blockade, but subsequently relapsed off therapy. Regression of both injected and noninjected lesions was observed. Gene expression analyses demonstrated increased IT infiltration by cytotoxic immune cells in both injected and noninjected tumors. The highest dose (32 mg) was selected for the Phase 2 stage. <h3>Conclusions</h3> IT administration of cavrotolimod appears to be safe and well tolerated in combination with pembrolizumab. Durable responses have occurred in patients previously experiencing progressive disease on PD-1 blockade. <h3>Trial Registration</h3> NCT03684785 <h3>Ethics Approval</h3> The study was approved by Institutional Review Boards of Dana-Farber Cancer Institute (IRB #18-584), John Wayne Cancer Institute (WIRB #20183064), University of Miami (IRB #20180957), University of Iowa (IRB #201810763), University of Cincinnati (WIRB #20183064), University of Washington (WIRB #20183064), MSKCC (IRB #20-174), UC San Francisco (WIRB #20183064), U Colorado (WIRB #20183064), Northwestern (IRB #STU00211083), U Arizona (WIRB #20183064), UC Irvine (WIRB #20183064), U Pitt (WIRB #20183064), and Washington University (WIRB #20183064)." @default.
• W3113180393 created "2020-12-21" @default.
• W3113180393 creator A5012069174 @default.
• W3113180393 creator A5015648461 @default.
• W3113180393 creator A5016531541 @default.
• W3113180393 creator A5017330947 @default.
• W3113180393 creator A5029723783 @default.
• W3113180393 creator A5034786338 @default.
• W3113180393 creator A5035539932 @default.
• W3113180393 creator A5036004013 @default.
• W3113180393 creator A5036875036 @default.
• W3113180393 creator A5054617686 @default.
• W3113180393 creator A5060495866 @default.
• W3113180393 creator A5061224094 @default.
• W3113180393 creator A5062517991 @default.
• W3113180393 creator A5064100640 @default.
• W3113180393 creator A5069069870 @default.
• W3113180393 creator A5069589605 @default.
• W3113180393 creator A5072305232 @default.
• W3113180393 creator A5074279819 @default.
• W3113180393 creator A5078755190 @default.
• W3113180393 creator A5084480627 @default.
• W3113180393 creator A5085103660 @default.
• W3113180393 creator A5088270651 @default.
• W3113180393 creator A5089182718 @default.
• W3113180393 creator A5090234654 @default.
• W3113180393 date "2020-11-01" @default.
• W3113180393 modified "2023-10-03" @default.
• W3113180393 title "423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors" @default.
• W3113180393 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0423" @default.
• W3113180393 hasPublicationYear "2020" @default.
• W3113180393 type Work @default.
• W3113180393 sameAs 3113180393 @default.
• W3113180393 citedByCount "2" @default.
• W3113180393 countsByYear W31131803932023 @default.
• W3113180393 crossrefType "proceedings-article" @default.
• W3113180393 hasAuthorship W3113180393A5012069174 @default.
• W3113180393 hasAuthorship W3113180393A5015648461 @default.
• W3113180393 hasAuthorship W3113180393A5016531541 @default.
• W3113180393 hasAuthorship W3113180393A5017330947 @default.
• W3113180393 hasAuthorship W3113180393A5029723783 @default.
• W3113180393 hasAuthorship W3113180393A5034786338 @default.
• W3113180393 hasAuthorship W3113180393A5035539932 @default.
• W3113180393 hasAuthorship W3113180393A5036004013 @default.
• W3113180393 hasAuthorship W3113180393A5036875036 @default.
• W3113180393 hasAuthorship W3113180393A5054617686 @default.
• W3113180393 hasAuthorship W3113180393A5060495866 @default.
• W3113180393 hasAuthorship W3113180393A5061224094 @default.
• W3113180393 hasAuthorship W3113180393A5062517991 @default.
• W3113180393 hasAuthorship W3113180393A5064100640 @default.
• W3113180393 hasAuthorship W3113180393A5069069870 @default.
• W3113180393 hasAuthorship W3113180393A5069589605 @default.
• W3113180393 hasAuthorship W3113180393A5072305232 @default.
• W3113180393 hasAuthorship W3113180393A5074279819 @default.
• W3113180393 hasAuthorship W3113180393A5078755190 @default.
• W3113180393 hasAuthorship W3113180393A5084480627 @default.
• W3113180393 hasAuthorship W3113180393A5085103660 @default.
• W3113180393 hasAuthorship W3113180393A5088270651 @default.
• W3113180393 hasAuthorship W3113180393A5089182718 @default.
• W3113180393 hasAuthorship W3113180393A5090234654 @default.
• W3113180393 hasConcept C104317684 @default.
• W3113180393 hasConcept C121608353 @default.
• W3113180393 hasConcept C126322002 @default.
• W3113180393 hasConcept C143998085 @default.
• W3113180393 hasConcept C150194340 @default.
• W3113180393 hasConcept C170493617 @default.
• W3113180393 hasConcept C185592680 @default.
• W3113180393 hasConcept C190727270 @default.
• W3113180393 hasConcept C2776999253 @default.
• W3113180393 hasConcept C2777701055 @default.
• W3113180393 hasConcept C2778468042 @default.
• W3113180393 hasConcept C2778938600 @default.
• W3113180393 hasConcept C2779138994 @default.
• W3113180393 hasConcept C2780057760 @default.
• W3113180393 hasConcept C502942594 @default.
• W3113180393 hasConcept C55493867 @default.
• W3113180393 hasConcept C71924100 @default.
• W3113180393 hasConceptScore W3113180393C104317684 @default.
• W3113180393 hasConceptScore W3113180393C121608353 @default.
• W3113180393 hasConceptScore W3113180393C126322002 @default.
• W3113180393 hasConceptScore W3113180393C143998085 @default.
• W3113180393 hasConceptScore W3113180393C150194340 @default.
• W3113180393 hasConceptScore W3113180393C170493617 @default.
• W3113180393 hasConceptScore W3113180393C185592680 @default.
• W3113180393 hasConceptScore W3113180393C190727270 @default.
• W3113180393 hasConceptScore W3113180393C2776999253 @default.
• W3113180393 hasConceptScore W3113180393C2777701055 @default.
• W3113180393 hasConceptScore W3113180393C2778468042 @default.
• W3113180393 hasConceptScore W3113180393C2778938600 @default.
• W3113180393 hasConceptScore W3113180393C2779138994 @default.
• W3113180393 hasConceptScore W3113180393C2780057760 @default.
• W3113180393 hasConceptScore W3113180393C502942594 @default.
• W3113180393 hasConceptScore W3113180393C55493867 @default.
• W3113180393 hasConceptScore W3113180393C71924100 @default.
• W3113180393 hasLocation W31131803931 @default.
• W3113180393 hasOpenAccess W3113180393 @default.
• W3113180393 hasPrimaryLocation W31131803931 @default.
• W3113180393 hasRelatedWork W2745455975 @default.
• W3113180393 hasRelatedWork W2969782175 @default.
• W3113180393 hasRelatedWork W3028354168 @default.

• next